Hong Qiaonan, Liu Jian, Wei Yuquan, Wei Xiawei
Department of Biotherapy, Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu 610041, China.
Vaccines (Basel). 2023 Jul 8;11(7):1218. doi: 10.3390/vaccines11071218.
Vaccination is one of the most effective strategies to control epidemics. With the deepening of people's awareness of vaccination, there is a high demand for vaccination. Hence, a flexible, rapid, and cost-effective vaccine platform is urgently needed. The baculovirus expression vector system (BEVS) has emerged as a promising technology for vaccine production due to its high safety, rapid production, flexible product design, and scalability. In this review, we introduced the development history of BEVS and the procedures for preparing recombinant protein vaccines using the BEVS platform and summarized the features and limitations of this platform. Furthermore, we highlighted the progress of the BEVS platform-related research, especially in the field of vaccine. Finally, we provided a new prospect for BEVS in future vaccine manufacturing, which may pave the way for future BEVS-derived vaccine development.
疫苗接种是控制疫情最有效的策略之一。随着人们对疫苗接种意识的不断提高，对疫苗接种的需求也很高。因此，迫切需要一个灵活、快速且具有成本效益的疫苗平台。杆状病毒表达载体系统（BEVS）因其高安全性、快速生产、灵活的产品设计和可扩展性，已成为一种有前途的疫苗生产技术。在这篇综述中，我们介绍了BEVS的发展历史以及使用BEVS平台制备重组蛋白疫苗的程序，并总结了该平台的特点和局限性。此外，我们强调了BEVS平台相关研究的进展，特别是在疫苗领域。最后，我们为BEVS在未来疫苗制造中的应用提供了新的前景，这可能为未来基于BEVS的疫苗开发铺平道路。
